Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Femasys Inc (FEMY)

Femasys Inc (FEMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,371
  • Shares Outstanding, K 22,898
  • Annual Sales, $ 1,070 K
  • Annual Income, $ -14,250 K
  • EBIT $ -17 M
  • EBITDA $ -17 M
  • 60-Month Beta -2.83
  • Price/Sales 18.93
  • Price/Cash Flow N/A
  • Price/Book 3.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.22
  • Number of Estimates 1
  • High Estimate -0.22
  • Low Estimate -0.22
  • Prior Year -0.19
  • Growth Rate Est. (year over year) -15.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8600 +17.44%
on 11/19/24
1.4000 -27.86%
on 10/30/24
-0.2850 (-22.01%)
since 10/21/24
3-Month
0.8600 +17.44%
on 11/19/24
1.4000 -27.86%
on 10/30/24
-0.0300 (-2.88%)
since 08/21/24
52-Week
0.7340 +37.60%
on 01/31/24
2.4000 -57.92%
on 03/04/24
+0.1080 (+11.97%)
since 11/21/23

Most Recent Stories

More News
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

FEMY : 1.0100 (+3.38%)
Femasys to Exhibit at the Annual AAGL 2024 Global Conference

FEMY : 1.0100 (+3.38%)
Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control

FEMY : 1.0100 (+3.38%)
Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeed

FEMY : 1.0100 (+3.38%)
Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program

FEMY : 1.0100 (+3.38%)
Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

FEMY : 1.0100 (+3.38%)
5 of the Most Active Penny Stocks Worth Your Precious Time

These are five of the Most Active Penny Stocks in October that investors may find worthy of investment for 2024 and beyond

CHPT : 1.1300 (+3.67%)
SABR : 3.67 (+1.94%)
FEMY : 1.0100 (+3.38%)
NKLA : 2.0300 (+6.28%)
GRAB : 5.67 (+0.18%)
Stock Index Futures Plunge as Investors Weigh Interest Rate Outlook

December S&P 500 futures (ESZ23) are down -0.40%, and December Nasdaq 100 E-Mini futures (NQZ23) are down -0.53% this morning as market participants continued to price in an extended period of elevated...

ESZ23 : 4,694.27s (-0.58%)
NQZ23 : 16,530.23s (-0.07%)
AMZN : 198.38 (-2.22%)
NVDA : 146.67 (+0.53%)
SEE : 35.53 (+1.34%)
HPQ : 37.91 (+3.35%)
COST : 955.65 (+2.97%)
CTAS : 221.49 (+1.25%)
FERG : 206.45 (+1.83%)
ASC.LN : 367.400 (+0.11%)
DKNG : 43.55 (-0.57%)
FEMY : 1.0100 (+3.38%)
Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2022 and Provides Corporate Update

Continued focus and progress with FemaSeed® and FemBloc® biomedical product candidates in developmentFemCerv® and FemCath™ commercial availability expected...

FEMY : 1.0100 (+3.38%)
Femasys To Host Key Opinion Leader Event on FemBloc, a First-of-its-Kind Medical Solution for Permanent Birth Control and an Important Option for Women Post Overturn of Roe v. Wade

Webinar to be held Thursday, July 28th @ 10:30am EDT...

FEMY : 1.0100 (+3.38%)

Business Summary

Femasys Inc.is a biomedical company focused on transforming women's healthcare by developing novel solutions as well as providing significant clinical impact to address severely underserved areas. The company's lead product candidates offer FemBloc and FemaSeed. Femasys Inc. is based in ATLANTA.

See More

Key Turning Points

3rd Resistance Point 1.1100
2nd Resistance Point 1.0700
1st Resistance Point 1.0400
Last Price 1.0100
1st Support Level 0.9700
2nd Support Level 0.9300
3rd Support Level 0.9000

See More

52-Week High 2.4000
Fibonacci 61.8% 1.7636
Fibonacci 50% 1.5670
Fibonacci 38.2% 1.3704
Last Price 1.0100
52-Week Low 0.7340

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar